Skip to main content
Wearable ECG

What an Irregular Heart Rhythm Notification Actually Confirms, and What It Doesn't Yet

The number most people have heard, 84 percent accurate, describes something narrower than most people assume, and the gap between the two numbers is the entire story.

KM
Kate Maren Editor, KnowYourPrime
Established · see the file
For information only. This is not medical advice, diagnosis, or treatment, and it cannot account for your own health history. A reading on a consumer device is not a clinical measurement. If a number worries you or you have symptoms, talk to a qualified healthcare provider. Full disclaimer.

Covers wrist-based irregular pulse notification accuracy specifically, based on the largest published smartwatch AFib screening trial. Does not cover diagnosed AFib management or stroke-risk treatment decisions.

An irregular heart rhythm notification from a watch is a real signal worth taking seriously, not a diagnosis on its own, and the largest published study of exactly this feature is explicit about the gap between the two.

The 84 Percent Figure and the 34 Percent Figure Are Answering Different Questions

A wrist device flags an irregular pulse by analyzing the timing pattern between heartbeats optically, looking for a pattern consistent with atrial fibrillation. It does not record an ECG on its own to confirm that pattern. In the largest published trial of this feature, just 0.52 percent of more than 419,000 participants ever received such a notification over a median of 117 days of monitoring.

Notified participants were mailed an ECG patch, a medical-grade recording device, to wear for confirmation. When the irregular pulse notification and the ECG patch data overlapped in time, the positive predictive value for atrial fibrillation was 84 percent, the figure most people have heard. But the patches were applied 13 days after notification on average, and among everyone who returned usable patch data, atrial fibrillation was confirmed in only 34 percent overall.

Both numbers are accurate, they describe different moments. Atrial fibrillation is often intermittent, coming and going over days or weeks, so a rhythm that was irregular enough to trigger a notification is not guaranteed to still be irregular two weeks later when the confirmation test starts. How wearable ECG detection actually works gets into the mechanism behind that gap, if that's the part you're actually curious about.

1 study
  • Among 419,297 participants monitored a median of 117 days, 0.52 percent received an irregular pulse notification. Positive predictive value for atrial fibrillation was 84 percent when the notification and ECG patch data were simultaneous, but atrial fibrillation was confirmed in only 34 percent of participants overall when patches were applied an average of 13 days after notification.Prospective pragmatic clinical trial · Perez et al., New England Journal of Medicine, 2019
Claim rating: Established · see the file

The Notification Rate Itself Is Part of the Picture

Separately from confirmation accuracy, a hypothesis-generating analysis of randomized AFib screening trials found continuous wearable-style screening in asymptomatic, high-risk populations nearly tripled AFib diagnoses and doubled anticoagulant use compared to unscreened controls, with overdiagnosis estimated at 8 to 29 percent depending on method. What that added diagnosis and treatment actually costs is a separate, deeper question this site covers on its own.

That population-level finding and the 34 percent follow-up figure point in a similar direction without being the same claim. One is about how much extra AFib gets found and treated across a screened population. The other is about how often a single individual notification holds up when tested again later.

This trial's participants volunteered through a smartphone app and were younger and healthier on average than the general population of AFib risk, so the 34 percent confirmation rate may not generalize directly to an older adult or someone with existing cardiovascular risk factors. The study also could not measure how many irregular-rhythm episodes went completely unnoticed and unnotified.

When an Irregular Rhythm Notification Is a Factual Reason to See a Doctor

A single notification with no symptoms, in someone without known heart disease, fits the pattern this evidence describes. A real signal worth following up. Not a confirmed diagnosis. Not every combination does. Chest pain, fainting, severe shortness of breath, or an irregular rhythm that comes with dizziness or lightheadedness is a factual reason to seek medical attention promptly, and repeated notifications over time are a factual reason to bring the pattern to a doctor for ECG-based evaluation even without those symptoms.

The notification's job is to flag a pattern worth checking. Confirming or ruling it out is a medical evaluation's job, not a watch's.

Common questions

Does an irregular heart rhythm notification mean I have AFib?

Not on its own. In the largest published trial of this feature, only 34 percent of notified participants who later wore a confirmatory ECG patch actually showed atrial fibrillation, though the notification itself is still a real signal worth medical follow-up.

Why is the accuracy sometimes reported as 84 percent and sometimes much lower?

The 84 percent figure describes positive predictive value when the notification and ECG patch data were recorded at the same time. The 34 percent figure describes confirmation when the patch was applied an average of 13 days after the notification, since AFib often comes and goes.

If I only got one notification and nothing since, should I still get it checked?

A single notification with no symptoms is the pattern most consistent with this evidence: a signal worth a medical follow-up, not an emergency. Repeated notifications, or any notification alongside chest pain, fainting, or severe shortness of breath, are factual reasons to act sooner.

Do more people get diagnosed with AFib because of these notifications?

Yes. Screening research found continuous wearable-style AFib screening nearly tripled diagnoses and doubled anticoagulant use in trial populations, with a meaningful share estimated to be overdiagnosis rather than clinically necessary treatment.